Vineet Laboratories Approves ₹30 Crore Rights Issue to Strengthen Capital Base

Hyderabad, November 27, 2025 – At today’s board meeting, Vineet Laboratories Ltd. announced that the board had approved the company’s Rights Issue of up to ₹30 crore. The funds from this will be used to strengthen the company’s existing capital base further and assist with future growth initiatives. In conjunction with this announcement, the Board formed a “Rights Issue Committee” whose primary responsibility will be to oversee the entire fundraising process.

Board Approves ₹30 Crore Rights Issue

Vineet Laboratories announced that it will issue additional equity shares of ₹10 each to its eligible shareholders of record on a later-determined date. Further information will be provided in a letter of offer regarding the ratio of entitlement, pricing, and due dates for applications. The primary purpose of this new rights offering is to help enhance the financial strength of Vineet Laboratories, thereby improving its ability to grow within the very competitive pharmaceutical industry.

Formation of Rights Issue Committee

The Board of Directors has formed the Rights Issue Committee, and it includes senior members of the board – Gaddam Venkata Ramana, Bhupathiraju Satyanarayana Raju, Vennapusa Premananda Reddy, and Acharekar Dilip. The Rights Issue Committee will be responsible for all aspects of the Rights Issue – planning, executing and completing the Rights Issue in compliance with applicable regulations, policies and procedures, and ensuring the smooth flow of activities throughout the Rights Issue process.

Meeting Timings And Next Steps

The board met at 11:30 AM and adjourned at 12:30 PM, according to a recent filing with regulators. The Company also indicated that a Letter of Offer would soon be sent to shareholders. This letter will specify who is eligible to participate in the rights issue and how to apply, as well as provide important dates for applying for the rights issue.

Share Market Snapshot

On 27 November 2025, following the announcement, the share price of Vineet Laboratories Ltd closed at ₹41.48, down 7.04% from its previous close of ₹44.62. The share opened at ₹45.20 and traded between ₹45.20 and ₹41.02, high and low for the day.

Vineet Laboratories Ltd is a Hyderabad-based manufacturer of pharmaceutical intermediates and fine chemicals that services both local and global customers. The company is publicly traded on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and positions itself to be a trusted partner to worldwide pharmaceutical companies.

REF: https://nsearchives.nseindia.com/corporate/VINEETLAB_27112025124333_Upload.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations